BICX · Biocorrx Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214.5K | - | $635.2K | $178.2K | $3.6K | - | $0 | $4.0K | - | $10.1K |
| Cost of Revenue | $25.2K | - | - | - | $1.7K | - | $0 | $0 | - | $3.9K |
| Gross Profit | $189.4K | - | - | - | $2.0K | - | $0 | $4.0K | - | $6.3K |
| R&D | $352.3K | - | $1.00M | $296.9K | $213.8K | - | $460.1K | $536.4K | - | $287.0K |
| SG&A | $775.5K | - | $1.15M | $1.22M | $750.1K | - | $1.19M | $711.0K | - | $674.5K |
| Total Operating Expenses | $1.17M | - | $2.58M | $1.59M | $972.3K | - | $1.66M | $1.37M | - | $972.0K |
| D&A | $24.8K | - | $6.7K | $72.0K | $6.7K | - | $6.4K | $6.7K | - | $6.7K |
| Operating Income | ($956.0K) | - | ($1.95M) | ($1.41M) | ($968.7K) | - | ($1.66M) | ($1.37M) | - | ($961.9K) |
| Interest Expense | $31.0K | - | $29.7K | $36.7K | $181.8K | - | $149.0K | $317.9K | - | $36.9K |
| Income Tax | $0 | - | - | $0 | $0 | - | $0 | $0 | - | $0 |
| Net Income | ($831.2K) | - | ($1.92M) | ($1.23M) | ($1.24M) | - | ($1.51M) | ($1.23M) | - | ($867.3K) |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.03) | - | ($0.14) | ($0.13) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $211.9K | $139.4K | $287.7K | $111.9K | $24.1K | $88.0K | $90 | $8.4K | $65.2K | $156.4K |
| Accounts Receivable | $330.3K | $253.5K | $194.4K | $51.2K | $112.0K | $0 | $0 | $0 | $740 | $35.4K |
| Inventory | $143.4K | $143.4K | $155.4K | $133.6K | $133.6K | - | - | - | - | - |
| Accounts Payable | $4.36M | $4.03M | $6.73M | $3.71M | $2.97M | $3.02M | $3.10M | $2.83M | $2.47M | $2.39M |
| Current Assets | $1.02M | $814.5K | $1.46M | $527.5K | $565.8K | $118.0K | $353.1K | $172.0K | $187.1K | $245.8K |
| Total Assets | $2.32M | $2.15M | $7.53M | $6.68M | $6.80M | $385.9K | $643.6K | $478.5K | $388.9K | $534.4K |
| Current Liabilities | $8.53M | $8.31M | $15.04M | $14.56M | $13.44M | $8.21M | $8.22M | $7.31M | $6.43M | $5.95M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $13.95M | $13.67M | $20.30M | $19.69M | $18.60M | $12.74M | $12.65M | $11.63M | $10.34M | $9.79M |
| Stockholders' Equity | ($11.45M) | ($11.22M) | ($13.48M) | ($12.62M) | ($11.56M) | ($12.12M) | ($11.83M) | ($11.00M) | ($9.82M) | ($9.13M) |
| Retained Earnings | ($87.48M) | ($86.65M) | ($87.20M) | ($85.28M) | ($84.05M) | ($83.21M) | ($82.04M) | ($80.56M) | ($78.10M) | ($77.13M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($433.0K) | - | - | - | ($339.7K) | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $505.5K | - | - | - | $375.5K | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 88.3% | - | - | - | 54.0% | - | - | 100.0% | - | 61.7% |
| Operating margin | -445.6% | - | -306.3% | -793.3% | -26759.4% | - | - | -33853.0% | - | -9481.2% |
| EBITDA margin | -434.0% | - | -305.2% | -752.9% | -26574.0% | - | - | -33687.0% | - | -9415.0% |
| Net margin | -387.4% | - | -301.9% | -692.0% | -34184.1% | - | - | -30506.7% | - | -8549.5% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 164.2% | - | 158.2% | 166.6% | 5907.0% | - | - | 13259.9% | - | 2828.6% |
| SG&A / Revenue | 361.5% | - | 180.3% | 686.3% | 20720.9% | - | - | 17577.9% | - | 6648.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -35.8% | - | -25.5% | -18.5% | -18.2% | - | -235.1% | -257.9% | - | -162.3% |
| Return on equity | 7.3% | - | 14.2% | 9.8% | 10.7% | - | 12.8% | 11.2% | - | 9.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.12 | 0.10 | 0.10 | 0.04 | 0.04 | 0.01 | 0.04 | 0.02 | 0.03 | 0.04 |
| Quick ratio | 0.10 | 0.08 | 0.09 | 0.03 | 0.03 | 0.01 | 0.04 | 0.02 | 0.03 | 0.04 |
| Cash ratio | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.03 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -30.8x | - | -65.6x | -38.5x | -5.3x | - | -11.1x | -4.3x | - | -26.1x |
| Equity multiplier | -0.20 | -0.19 | -0.56 | -0.53 | -0.59 | -0.03 | -0.05 | -0.04 | -0.04 | -0.06 |
| Liabilities / Assets | 6.00 | 6.37 | 2.69 | 2.95 | 2.74 | 33.01 | 19.65 | 24.30 | 26.59 | 18.33 |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.08 | 0.03 | 0.00 | - | 0.00 | 0.01 | - | 0.02 |
| Inventory turnover | 0.18 | - | - | - | 0.01 | - | - | - | - | - |
| Days sales outstanding | 562d | - | 112d | 105d | 11289d | - | - | 0d | - | 1273d |
| Days inventory outstanding | 2079d | - | - | - | 29252d | - | - | - | - | - |
| Days payable outstanding | 63121d | - | - | - | 649759d | - | - | - | - | 224764d |
| Cash conversion cycle | -60480d | - | - | - | -609218d | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 47.7x | - | 3.6x | - | 404.6x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | 4306.4% | -91.0% | - | -100.0% | -79.4% | - | -89.3% |
| Revenue CAGR (3y) | 74.4% | - | 88.8% | 123.3% | -29.0% | - | - | -36.4% | - | -30.2% |
| Revenue CAGR (5y) | 84.2% | - | 84.4% | 39.5% | -52.4% | - | - | -47.2% | - | -33.6% |
| Gross profit growth (YoY) | - | - | - | - | -93.9% | - | - | -56.3% | - | -93.2% |
| Operating income growth (YoY) | - | - | -17.2% | -3.3% | 8.3% | - | -72.6% | -44.6% | - | 6.5% |
| Net income growth (YoY) | - | - | -26.8% | 0.0% | -22.5% | - | -74.4% | -33.6% | - | 8.8% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 7.4% | -14.0% | -14.8% | -32.8% | -23.4% | -29.6% | -28.2% | -19.8% | -29.0% |
Peer comparison
Same SIC group: Services-Specialty Outpatient Facilities, NEC
Comparing BioCorRx Inc. against the 5 most active filers in the same SIC group.